Granules India Limited (NSE: GRANULES) reported Revenue from Operations for Q3 FY23 of ₹1,146.12 Crore up from ₹996.76 Crore year on year,
Categories
pharmaceuticals
SUVEN PHARMACEUTICALS LTD (SUVEN) Q3 FY23 Earnings Concall Transcript
SUVEN PHARMACEUTICALS LTD (NSE:SUVEN) Q3 FY23 Earnings Concall dated Feb. 07, 2023. Corporate Participants: Rishab Barar -- Investor Relations Venkat Jasti -- Managing Director Venkatraman Sunder -- Vice
Aarti Industries Ltd Q3 FY23 Earnings Conference Call Insights
Key highlights from Aarti Industries Ltd (AARTIIND) Q3 FY23 Earnings Concall Management Update: [00:04:16] AARTIIND said demand for textile products was impacted
Gujarat Themis Biosyn Limited (506879) Q3 FY23 Earnings Concall Transcript
Gujarat Themis Biosyn Limited (NSE:506879) Q3 FY23 Earnings Concall dated Feb. 06, 2023. Corporate Participants: Sachin Patel -- Director Rajneesh Anand -- Consultant Analysts: Saloni Hemnani -- Molecule
Aarti Industries Ltd (AARTIIND) Q3 FY23 Earnings Concall Transcript
Aarti Industries Ltd (NSE: AARTIIND) Q3 FY23 Earnings Concall dated Feb. 06, 2023 Corporate Participants: Nishid Solanki -- Investor Relations Rajendra Gogri -- Chairman and Managing
Jubilant Pharmova Limited (JUBLPHARMA ) Q3 FY23 Earnings Concall Transcript
Jubilant Pharmova Limited (NSE:JUBLPHARMA) Q3 FY23 Earnings Concall dated Feb. 03, 2023. Corporate Participants: Vineet Mayer -- Investor Relations and Corporate Finance Shyam S
GMM Pfaudler Limited (GMMPFAUDLR) Q3 FY23 Earnings Concall Transcript
GMM Pfaudler Limited (NSE:GMMPFAUDLR) Q3 FY23 Earnings Concall dated Feb. 03, 2023. Corporate Participants: Priyanka Daga -- Deputy General Manager Tarak Patel -- Managing Director Manish
Divis Labs Ltd.(NSE:DIVISLAB )|Q3 FY23 Results Out|Total Income rises 5% yoy
Divi's Laboratories Limited (NSE: DIVISLAB) is a pharmaceutical company specializing in the manufacture of active pharmaceutical ingredients (APIs) and intermediates. The company
Jubilant Pharmova Limited Q3 FY23; Revenue Increased By 18%
Jubilant Pharmova Limited (NSE: JUBLPHARMA) reported a Revenue from Operations of ₹1,533.22 Crores, a boost of 18% growth from the previous year.
Alembic Pharmaceuticals Limited (APLLTD) Q3 FY23 Earnings Concall Transcript
Alembic Pharmaceuticals Limited (NSE:APLLTD) Q3 FY23 Earnings Concall dated Feb. 01, 2023. Corporate Participants: R.K. Baheti -- Director, Finance and Chief Financial Officer Shaunak
Sun Pharmaceutical Industries Limited (SUNPHARMA) Q3 FY23 Earnings Concall Transcript
Sun Pharmaceutical Industries Limited (NSE: SUNPHARMA) Q3 FY23 Earnings Concall dated Jan. 31, 2023 Corporate Participants: Abhishek Sharma -- Head of Investor Relations and
Laurus Labs Limited Q3 FY23 Earnings Conference Call Insights
Key highlights from Laurus Labs Limited (LAURUSLABS) Q3 FY23 Earnings Concall Management Update: [00:03:57] LAURUSLABS said its strong results were driven by
Glenmark Life Sciences Limited Q3 FY23 Earnings Conference Call Insights
Key highlights from Glenmark Life Sciences Limited (GLS) Q3 FY23 Earnings Concall Q&A Highlights: [00:13:44] Tarang Agrawal of Old Bridge enquired about
Laurus Labs Limited Q3 FY23; Consolidated Revenue Jumps By 50%
Laurus Labs Limited (NSE: LAURUSLABS) reported Revenue from Operations for Q3 FY23 of ₹1,544.82 Crore up from ₹1028.76 Crore year on year,
Torrent Pharmaceuticals Ltd Q3 FY23 Earnings Conference Call Insights
Key highlights from Torrent Pharmaceuticals Ltd (TORNTPHARM) Q3 FY23 Earnings Concall Management Update: [00:05:39] TORNTPHARM said the company expects to file about
Torrent Pharmaceuticals Ltd (TORNTPHARM) Q3 FY23 Earnings Concall Transcript
Torrent Pharmaceuticals Ltd (NSE: TORNTPHARM) Q3 FY23 Earnings Concall dated Jan. 25, 2023 Corporate Participants: Sudhir Menon -- Executive Director, (Finance) and Chief Financial
Infographic Ltd.(NSE: DRREDDY) | Q3 FY23 Results | Total Income rises +7.47% qoq
Dr. Reddy's Laboratories (NSE: DRREDDY) is an Indian multinational pharmaceutical company. Founded in 1984, the company primarily develops and sells a wide
Infographic Cipla Ltd.(NSE: CIPLA) | Q3 FY23 Results | Total Income falls -0.45% qoq
Cipla Limited (NSE: CIPLA) is an Indian multinational pharmaceutical and biopharmaceutical company. Founded in 1935, Cipla primarily develops and sells generic and
Gland Pharma Limited Q3 FY23 Earnings Conference Call Insights
Key highlights from Gland Pharma Limited (GLAND) Q3 FY23 Earnings Concall Management Update: [00:06:08] GLAND said the insulin line is in the
Gland Pharma Limited Q3 FY23; Net Profit Down To 232 Crore
Gland Pharma Limited (NSE: GLAND) reported Revenue from Operations of ₹938.28 Crore down from ₹1,063.32 Crore year on year, a decline of
Marksans Pharma(NSE:MARKSANS): Everything You Need to Know | Stock up 30% in 3 Months
Marksans Pharma (NSE:MARKSANS) is a mid-sized pharmaceutical company with a large presence in the US, UK, Australia, and New Zealand markets. forward-integrated